Stockreport

Bolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF –   BDC-1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022 –   Cash balance of $246.8 million expected to fund key [Read more]